ERBB2 and non-small cell lung carcinoma: This study showed that patients with HER2-mutated NSCLC had less metastasis compared with wild type (28.3% vs. 47.4%, P = 0.014), however, Le Y reported that HER2 positivity was associated with interpulmonary metastasis, but the intrapulmonary metastasis rate in patients with HER2 mutant NSCLC was only 4.3% in this study (39).